NCT03745989: Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, RAF
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinically active central nervous system metastases and/or carcinomatous meningitis; Patients who have received prior therapy with an MEK inhibitor (e.g. cobimetinib, trametinib), or an ERK inhibitor (e.g. MK-8353, GCD-0994, ulixertinib), or a BRAF inhibitor (e.g. dabrafenib, vemurafenib)

Comments are closed.

Up ↑